Printer Friendly Page

Human BioSystems, Inc., (OTC-BB:HBSC) a development stage company, engages in the development of preservation platforms for organs and other biomaterials. The company is developing proprietary above zero (HBS-AZ) and below zero (HBS-BZ) organ and issue preservation systems and methods for preserving platelets, red blood cells, heart valves, tissues, and organs. Its technologies would extend the shelf life of blood platelets and other biological material. The company's target customers include blood banks, hospitals, clinics, and similar organizations. It operates in the United States and Russia.

Human BioSystems was founded in February 1998 after more than ten years of research. We believe that our proposed technology represents a breakthrough in the storage and preservation of living biological materials that promises to reduce the waste and added cost factors of current technologies, while simultaneously increasing the worldwide availability of precious living biological materials needed to save human lives.

HBS has four issued patents (with others pending) for technologies that preserve platelets (a blood component used by chemotherapy, trauma, and other patients to stop bleeding) and organs such as the kidney, heart, liver, and lung. These technologies are being developed for commercialization.

The HBS platelet technology is being developed through intensive testing at blood centers and the organ storage technology is being developed through animal testing at our laboratory and research facilities. Additionally, two independent research labs have completed testing of our preservation technology for platelets, and the licensing process is underway with the FDA.

We believe that our technologies may be recognized as unique and revolutionary in their ability to extend and maintain functionality and quality of these materials for much longer periods of time than is currently possible, without the use of toxic solutions.

Our technologies consist of unique solutions and methods. Commercialization may include proprietary devices, solutions, and other disposables. Our goal is to extend the shelf life of platelets and organs well past the current standards. A longer storage life will benefit patients, surgeons, hospitals and insurance companies. HBS's opportunity in the blood platelet market is expected to exceed 300 millionin 2006 and further expected to grow an additional ten percent each year thereafter.

SAVING LIVES

Our goal is to be a leader in the development of technologies that provide safe, high quality, and longer shelf life of biological materials that are used in saving lives.

Today, the storage time for blood platelets, the congealing component of blood, is limited to a government-mandated period of 5 days after they are donated. In Japan the storage time is only 3 days. These short shelf lives create logistical problems and losses due to outdating (discarding).

With four patents issued and others pending, we are researching and developing unique methods and technologies to preserve platelets for extended periods and intend to market a platelet preservation system that is safe, practical and cost effective. HBS technology and equipment may allow blood centers and

hospitals to recover more than$500 million in lost revenue annually in North America, Western Europe and Japan. The HBS system for extending the preservation time of donor organs, currently under development, is expected to cost less and provide several vital advantages and benefits over currently available preservation solutions.